High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms

Simple item page
dc.contributor.authorAjetunmobi, Olabayo H.
dc.contributor.authorWall, Gina
dc.contributor.authorVidal Bonifacio, Bruna
dc.contributor.authorMartinez Delgado, Lucero A.
dc.contributor.authorChaturvedi, Ashok K.
dc.contributor.authorNajvar, Laura K.
dc.contributor.authorWormley, Floyd L.
dc.contributor.authorPatterson, Hoja P.
dc.contributor.authorWiederhold, Nathan P.
dc.contributor.authorPatterson, Thomas F.
dc.contributor.authorLopez-Ribot, Jose L.
dc.date.accessioned2023-09-27T12:36:19Z
dc.date.available2023-09-27T12:36:19Z
dc.date.issued2023-08-27
dc.date.updated2023-09-27T12:36:20Z
dc.description.abstractCandidiasis is one of the most frequent nosocomial infections affecting an increasing number of at-risk patients. Candida albicans remains the most frequent causative agent of candidiasis, but, in the last decade, C. auris has emerged as a formidable multi-drug-resistant pathogen. Both species are fully capable of forming biofilms, which contribute to resistance, increasing the urgency for new effective antifungal therapies. Repurposing existing drugs could significantly accelerate the development of novel therapies against candidiasis. Here, we have screened the Repurposing Hub library from the Broad Institute, containing over 6000 compounds, in search for inhibitors of C. albicans and C. auris biofilm formation. The primary screen identified 57 initial hits against C. albicans and 33 against C. auris. Confirmatory concentration-dependent assays were used to validate the activity of the initial hits and, at the same time, establish their anti-biofilm potency. Based on these results, ebselen, temsirolimus, and compound BAY 11-7082 emerged as the leading repositionable compounds. Subsequent experiments established their spectrum of antifungal activity against yeasts and filamentous fungi. In addition, their in vivo activity was examined in the murine models of hematogenously disseminated C. albicans and C. auris infections. Although promising, further in vitro and in vivo studies are needed to confirm their potential use for the therapy of candidiasis and possibly other fungal infections.
dc.description.departmentMolecular Microbiology & Immunology
dc.identifierdoi: 10.3390/jof9090879
dc.identifier.citationJournal of Fungi 9 (9): 879 (2023)
dc.identifier.urihttps://hdl.handle.net/20.500.12588/2074
dc.rightsAttribution 4.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCandida spp.
dc.subjectbiofilm
dc.subjectrepurposing
dc.subjectscreening
dc.subjectantifungal
dc.titleHigh-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
jof-09-00879.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

College of Sciences Faculty Research